As the Society for Immunotherapy of Cancer (SITC) annual meeting kicks off in Houston, we are honored that SUPLEXA, Alloplex Biotherapeutics’ groundbreaking immunotherapy platform, has been recognized among the Top 100 presentations. This recognition speaks to SUPLEXA’s potential as a new approa...
Category: Clinical
-
November 6, 2024
Join Us at SITC 2024 to Discover SUPLEXA’s Breakthrough Potential in Cancer Immunotherapy.
-
October 30, 2024
Cancer trial: retraining immune cells offers new hope for patients in personalized medicine breakthrough
In a remarkable development for cancer research, patients with advanced-stage cancer have benefited from SUPLEXA, a personalized treatment that trains the patient’s own immune cells to fight cancer. “Cancer often gains the upper hand by suppressing the immune system. Our approach flips the scrip...
-
September 7, 2023
Two abstracts on Alloplex’s lead technology platform, SUPLEXA, accepted for presentation at SITC23
Dr. Rohit Joshi of CRSA and Alloplex's leadership team will present the latest developments and data from SUPLEXA-101 phase 1 in-human trials in San Diego, CA (November 1 - 5, 2023)
The Society for Immunotherapy of Cancer has accepted two abstracts in relation to the trial of Alloplex’s lead technology platform, SUPLEXA, for presentation at this year’s 38th annual SITC meeting and conference. The posters to be presented by Dr. Rohit Joshi, alongside the Alloplex lea...
-
April 19, 2023
Alloplex to present emerging data from SUPLEXA-101 trial at World Oncology Cell Therapy Congress 2023 in Boston
The presentation will also highlight the development of an unprecedented blood-based pharmacodynamic signature of SUPLEXA activity
We are pleased to announce that Dr. Frank Borriello, Founder and CEO of Alloplex Biotherapeutics, will be presenting at the upcoming World Oncology Cell Therapy Congress, being held in Boston, MA, on April 25 & 26, 2023. The presentation will include emerging data from t...
-
December 15, 2022
Alloplex opens third prestigious site for SUPLEXA-101 first-in-class cellular therapy trial in oncology patients
Southern Oncology Clinical Research Unit in Adelaide joins Cancer Research SA, also in Adelaide, and Gallipoli Medical Research Foundation of Brisbane for the Phase 1 trial of Alloplex Biotherapeutics' autologous SUPLEXA cell immunotherapy.
Alloplex Biotherapeutics today announced the opening of the third site in its first-in-human clinical trial of SUPLEXA: Southern Oncology Cancer Research Unit ‘SOCRU’. SUPLEXA therapy is a highly-differentiated, autologous, non-engineered, multi-cellular therapy derived from patient peripheral b...
-
August 1, 2022
Independent Data Safety Monitoring Board agrees to continue enrollment in SUPLEXA first-in-human trial
No safety signals or adverse events were observed in the first cohort of three patients with solid cancer who have completed treatment with Alloplex Biotherapeutics Inc.'s SUPLEXA Therapeutic Cells.
On Friday 29 August, an independent Data Safety Monitoring Board ‘DSMB’ unanimously agreed that the trial of Alloplex Biotherapeutics Inc.’s SUPLEXA Therapeutic Cells should to continue to full enrollment.
-
July 27, 2022
Dr. Frank Borriello to speak at Gamma Delta T Therapies Summit.
July 28, 2022 in Boston.
Alloplex’s Founder and CEO, Dr. Frank Borriello, will be speaking at the 3rd Gamma Delta T Therapies Summit on Thursday 28th July 2022 at 11am in a session titled “Reviewing the clinical safety and efficacy of gamma delta therapies” on the Response in Solid Tumors of Non-Engineered Autologous...
-
April 29, 2022
Alloplex Biotherapeutics announces opening of first clinical trial site
Phase 1 trial of autologous SUPLEXA cell immunotherapy, commences in Adelaide South Australia
Alloplex Biotherapeutics announced today the site opening for its first-in-human clinical trial of SUPLEXA. SUPLEXA therapy is a highly-differentiated, autologous, non-engineered, multi-cellular therapy derived, from patient peripheral blood mononuclear cells. This Phase 1 is a first-in-human, open-...
-
January 17, 2022
Human Research Ethics Committee (HREC) in Australia approves the start of the first SUPLEXA Phase 1 Clinical Trial
Alloplex Biotherapeutics, Inc. (‘Alloplex’) – a private cellular therapeutics company dedicated to developing and commercializing a global first-in-class cellular therapeutic in oncology – today announced that the Human Research Ethics Committee (HREC) in Australia has approved the clinical...